Tempus Announces Multi-Year Collaboration with Moderna and Merck

Said Francis, Chief Business Officer and General Manager, Individualized Neoantigen Therapies at Moderna

“Bringing an individualized therapy like intismeran autogene from clinical development toward potential commercialization requires a seamless, highly reliable diagnostic network”

Said Francis, Chief Business Officer and General Manager, Individualized Neoantigen Therapies at Moderna

“Working with Tempus allows us to leverage their commercial footprint and advanced sequencing capabilities as we work to deliver individualized neoantigen therapies to patients at scale.”

Jannie Oosthuizen, President, Global Oncology and MSD International

“What makes individualized neoantigen therapies so exciting is that every treatment is designed around the biology of an individual patient's tumor.”

Jannie Oosthuizen, President, Global Oncology and MSD International

“That requires a carefully coordinated end-to-end process, from collecting a patient's tumor sample and generating sequencing data to designing and manufacturing an individualized therapy”

Jannie Oosthuizen, President, Global Oncology and MSD International

“Collaborations like this one with Tempus are helping build the infrastructure needed to bring this innovative approach to patients.”

Eric Lefkofsky, Founder and CEO of Tempus

“Individualized therapies represent the future of precision medicine, but delivering on their promise requires an end-to-end clinical workflow that works in the real world”

Eric Lefkofsky, Founder and CEO of Tempus

“By combining our operational scale and deep clinical integration with Merck and Moderna’s mRNA innovation, we are building the infrastructure needed to bring individualized cancer vaccines to patients.”